dihexa microsomal clearance (PNB-0408) | c-Met/HGFR Activator WO2014052766A1 - Hepatocyte growth factor

Factors influencing disease progression in autosomal dominant cerebellar ataxia and spastic paraplegia

the bone defects of the seventh group were filled with an autologous cortical graft

248, 249 Given the non-significant findings from the RCT and the potential hazards associated with long-term antibiotic administration in general (e.g., fostering of antibiotic resistant organisms), the Panel judged that antibiotic treatment is contraindicated in patients who have previously been administered antibiotics without efficacy and who present with a negative urine culture

, , ,- L- (L-PHE) L- (L-GLN), : L-PHE+Ch 2 2 - L-PHE Ch 2 2 - L-Gln+Ch 2 2 - L-Gln Ch 2 2 - 2

Always watch for regulatory updates, especially for Category 1 and 2 status on FDA lists